Canine osteoarthritis causes chronic pain in millions of dogs, and multimodal management significantly improves welfare outcomes beyond single drug approaches.
Arthritis is the most common source of chronic pain in the canine population, yet it is both underdiagnosed and undertreated. Many owners attribute slowing, stiffness, and reduced play to normal ageing rather than treatable pain. The welfare burden is enormous: millions of dogs live with daily pain that significantly reduces their quality of life and engagement with their environment and owners. Multimodal management, combining appropriate medication with weight management, physiotherapy, and environmental adaptation, produces outcomes significantly better than any single intervention alone. The development of anti-nerve growth factor therapy has added a powerful tool with excellent tolerability, expanding options particularly for dogs who cannot tolerate NSAIDs.